GH Research (NASDAQ:GHRS) Sees Strong Trading Volume – Should You Buy?

Shares of GH Research PLC (NASDAQ:GHRS) saw strong trading volume on Wednesday . Approximately 469,567 shares changed hands during mid-day trading, an increase of 52% from the previous session’s volume of 308,722 shares.The stock last traded at $30.38 and had previously closed at $29.08.

Key Stories Impacting GH Research

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for GH Research across several periods, including FY2026 EPS to ($1.14) from ($1.21) and FY2027 EPS to ($1.62) from ($1.64). The firm also modestly improved estimates for the second, third and fourth quarters of 2027. These revisions indicate expectations for somewhat narrower losses and reinforce HC Wainwright’s Buy rating.
• Positive Sentiment: The analyst’s long-term estimates project improving results by FY2030, when the expected loss narrows to ($1.22) per share from projected losses of ($1.76) in FY2028 and ($2.11) in FY2029. While GH Research remains pre-profit, the trajectory may support bullish sentiment among investors focused on the company’s longer-term development prospects.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting date. This provides no evidence of meaningful short-covering activity or a short-squeeze catalyst behind the recent strength.
• Negative Sentiment: GH Research is still expected to post losses in every forecast period provided, including a consensus loss of ($1.33) per share for the current year. The company’s valuation and stock performance therefore remain highly dependent on future clinical and commercial progress rather than near-term earnings.

Wall Street Analyst Weigh In

A number of research firms recently commented on GHRS. Wells Fargo & Company started coverage on GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price target on the stock. Zacks Research downgraded GH Research from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Needham & Company LLC increased their target price on GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Guggenheim raised their target price on GH Research from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $45.00.

GH Research Stock Up 2.1%

The stock’s 50-day moving average price is $25.88 and its 200-day moving average price is $20.37. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -29.68 and a beta of 1.29.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. On average, equities research analysts anticipate that GH Research PLC will post -1.33 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its position in shares of GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after acquiring an additional 780 shares during the last quarter. Troluce Capital Advisors LLC boosted its holdings in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Renaissance Technologies LLC bought a new position in GH Research in the first quarter valued at about $290,000. North Star Investment Management Corp. acquired a new stake in GH Research in the first quarter worth about $31,000. Finally, Avoro Capital Advisors LLC acquired a new stake in GH Research in the fourth quarter worth about $22,860,000. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.